Medigen Biotechnology (ROCO:3176) Other Current Payables: NT$230 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
54 GF Score
Price NT$32.35
GF Value NT$49.87
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medigen Biotechnology Other Current Payables?

Medigen Biotechnology ROCO:3176 -3.14% 54 Other Current Payables is NT$230 Mil as of Dec. 2025. GuruFocus rates ROCO:3176 with a GF Score™ of 54/100 and a GF Value™ of NT$49.87 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Medigen Biotechnology's Other Current Payables for the quarter that ended in Dec. 2025 was NT$230 Mil.

Medigen Biotechnology's quarterly Other Current Payables declined from Jun. 2025 (NT$258 Mil) to Sep. 2025 (NT$210 Mil) but then increased from Sep. 2025 (NT$210 Mil) to Dec. 2025 (NT$230 Mil).

Medigen Biotechnology's annual Other Current Payables declined from Dec. 2023 (NT$305 Mil) to Dec. 2024 (NT$235 Mil) and declined from Dec. 2024 (NT$235 Mil) to Dec. 2025 (NT$230 Mil).

Medigen Biotechnology Other Current Payables Related Terms

Medigen Biotechnology Other Current Payables Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Other Current Payables Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 308.03 319.39 304.82 234.92 230.21

Medigen Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.92 191.91 257.72 209.96 230.21
ROCO:3176
54GF Score
Medigen Biotechnology Corp ROCO:3176
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$230 Mil mean?
Medigen Biotechnology (ROCO:3176) has a Other Current Payables of NT$230 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Other Current Payables too high?
Medigen Biotechnology's current Other Current Payables is NT$230 Mil. Overall, Medigen Biotechnology has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Other Current Payables compare to VRTX and REGN?
Medigen Biotechnology's Other Current Payables of NT$230 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Other Current Payables is NT$230 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$49.87, compared to a current price of NT$32.35 — trading 35.1% below its estimated fair value. The current Other Current Payables is NT$230 Mil. Medigen Biotechnology's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Other Current Payables is NT$230 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$32.35 is trading 35.1% below its estimated GF Value™ of NT$49.87. GuruFocus considers Medigen Biotechnology to be Significantly Undervalued.

Key valuation signals for ROCO:3176:

  • Other Current Payables: NT$230 Mil
  • GF Value™: NT$49.87 vs. price of NT$32.35 (35.1% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
54GF Score

Get the complete analysis for ROCO:3176

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.35
Price
NT$49.87
GF Value